Patent Application
20100224192
The present invention is generally directed to oxygen delivery systems and methods. More particularly, the present invention is directed to an automated oxygen delivery method.
Many patients require respiratory support, including additional oxygen and/or assisted ventilation. Infants, particularly those born before term, may be unable to maintain adequate respiration and require support in the form of a breathing gas mixture combined with ventilatory assistance. The breathing gas mixture has an elevated fraction of oxygen (FiO2) compared to room air, while the ventilatory assistance provides elevated pressure at the upper airway. A significant number of infants receiving respiratory support will exhibit episodes of reduced blood oxygen saturation, or desaturation, i.e., periods in which oxygen uptake in the lungs is inadequate and blood oxygen saturation falls. These episodes may occur as frequently as twenty times per hour, and each episode must be carefully managed by the attending health care professional.
Most prior art systems require the attendant to monitor the blood oxygen saturation and manually adjust the ventilator settings to provide additional oxygen as soon as desaturation is detected. Similarly, the attendant must reduce the oxygen delivered to the patient once the blood oxygen saturation has been restored to a normal range. Failure to provide additional oxygen rapidly to the patient can lead to hypoxic ischemic damage, including neurological impairment, and, if prolonged, may cause death. Similarly, failure to reduce the oxygen delivered to the patient following recovery also has clinical sequelae, the most frequent of which is Retinopathy of Prematurity, a form of blindness caused by oxidation of the optical sensory neurons. While at least one prior art system has attempted to close a control loop around delivered FiO2 by using measured arterial hemoglobin oxygen saturation levels in the patient, this system does not safely and adequately detect and accommodate invalid measurement data, placing the patient at risk for at least those conditions noted above.
Accordingly, an improved oxygen delivery system is needed that automatically and safely controls the amount of oxygen delivered to a patient based on the amount of oxygen that is measured in the bloodstream and the status information associated with the measurement.
Embodiments of the present invention advantageously provide a method of automatically delivering oxygen to a patient.
In one embodiment, a desired concentration of oxygen in a bloodstream of a patient is received from a user. Data, including a measurement of the amount of oxygen in the bloodstream of the patient, as well as status information associated with the measurement, is received from a sensor. The measured data are then determined to be valid or invalid based on the measurement value and the status information, and, based on this determination, a delivered fraction of inspired oxygen is delivered to the patient. If the measured data are determined to be valid, then the delivered fraction of inspired oxygen is based on the desired oxygen concentration and the measured data. On the other hand, if the measured data are determined to be invalid, then the delivered fraction of inspired oxygen is set to a predetermined value.
There has thus been outlined, rather broadly, certain embodiments of the invention in order that the detailed description thereof herein may be better understood, and in order that the present contribution to the art may be better appreciated. There are, of course, additional embodiments of the invention that will be described below and which will form the subject matter of the claims appended hereto.
In this respect, before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of embodiments in addition to those described and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.
As such, those skilled in the art will appreciate that the conception upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.
The invention will now be described with reference to the drawing figures, in which like reference numerals refer to like parts throughout.
In a preferred embodiment, sensor 10 is a Masimo Signal Extraction pulse oximeter sensor (Masimo Corporation, Irvine, Calif.) that measures the absorption of light in two different wavelengths, such as red and infrared light, from which that fraction of the red blood cells in the optical pathway that are carrying oxygen, and hence the amount of oxygen in the patient's bloodstream, can be determined. In this embodiment, sensor module 12 is a Masimo interface board, such as the MS-11, MS-13, etc., sensor 10 is an Masimo pulse oximeter sensor, such as the LNCS (or LNOP) Adtx, Pdtx, Inf, Neo, NeoPt, etc., that is coupled to control subsystem 20 though sensor module 12 and attendant interface cables. Sensor module 12 includes a microcontroller, digital signal processor and supporting circuitry to drive the active components within sensor 10, such as red and infrared LEDs, capture the light signals generated by sensor 10, process these signals, and generate measurement data and status information associated with the sensor. Sensor module 12 calculates the saturation of peripheral oxygen, SPO2, in the bloodstream of the patient and the pulse rate of the patient based on these light signals, generates status information associated with the SPO2 data, including, for example, a perfusion index, a signal quality index, etc., and communicates this data to control subsystem 20 through sensor interface 14, such as an RS-232 serial interface. Alternatively, sensor module 12 may be incorporated within control subsystem 20 itself, replacing sensor interface 14.
In this embodiment, the perfusion index is the fractional variation in the optical absorption of oxygenated red blood cells between the systole and diastole periods of an arterial pulse. The signal quality index generally provides a confidence metric for the SPO2, and, in this pulse oximeter embodiment, the signal quality index is based on variations in the optical absorption related to, and not related to, the cardiac cycle. Additionally, sensor module 12 may identify measurement artifacts or sensor failures, such as optical interference (e.g., too much ambient light), electrical interference, sensor not detected, sensor not attached, etc., and provide this status information to control subsystem 20. In an alternative embodiment, sensor module 12 may provide red and infrared plethysmorgraphic signals directly to sensor interface 14 at a particular sample resolution and sample rate, such as, for example, 4 bytes/signal and 60 Hz, from which the SPO2 is calculated directly by control subsystem 20. These signals may be processed, averaged, filtered, etc., as appropriate, and used to generate the perfusion index, the signal quality index, various signal metrics, etc.
In another embodiment, sensor 10 is a transcutaneous gas tension sensor, such as, for example, a Radiometer TCM 4 or TCM40 transcutaneous monitor (Radiometer Medical ApS, Brønshøj, Denmark), that directly measures the partial pressure of oxygen in arteriolar blood, i.e., the blood in the surface capillary blood vessels, using a gas permeable membrane placed in close contact with skin. The membrane is heated to between 38° C. and 40° C. to encourage the surface blood vessels to dilate, and oxygen diffuses through the skin surface and the permeable membrane until the oxygen partial pressure inside the sensor is in equilibrium with the oxygen partial pressure in the blood. The transcutaneous gas tension sensor includes electrochemical cells, with silver and platinum electrodes and a reservoir of dissolved chemicals, that directly detect oxygen as well as carbon dioxide in solution in the blood. The measurement data provided by this sensor include arterial oxygen partial pressure measurement, PtcO2, and arterial carbon dioxide partial pressure measurement, PtcCO2, while status information may include heat output, sensor temperature, and skin perfusion. These data may be supplemented by additional information acquired by a pulse oximeter. In this transcutaneous gas tension embodiment, sensor module 12 may be provided as an independent module, or as a component within control subsystem 20.
In yet another embodiment, sensor 10 is an invasive catheter blood analyzer, such as, for example, a Diametric Neocath, Paratrend or Neotrend intra-arterial monitor, that is inserted into a blood vessel and directly measures various chemical constituents of the blood, such as O2, CO2, pH, etc., using chemoluminescent materials which either produce, or absorb, particular wavelengths of light depending the quantity of dissolved molecules in proximity to the sensor. The light is then transmitted along an optical fiber in the catheter to an external monitor device, such as sensor module 12. The measurement data provided by this sensor include dissolved oxygen in the blood, pO2, dissolved carbon dioxide in the blood, pCO2, blood acidity pH, and blood temperature. In this invasive catheter blood analyzer embodiment, sensor module 12 may be provided as an independent module or as a component within control subsystem 20.
Control subsystem 20 controls all of the ventilator functions, sensor measurement processing, gas calculations, monitoring and user interface functions. In a preferred embodiment, control subsystem 20 includes, inter alia, display 24, one or more input device(s) 26, sensor interface 14, pneumatics subsystem interface 28 and one or more processor(s) 22 coupled thereto. For example, display 24 may be a 12.1-inch, 800×600 backlit, active matrix liquid crystal display (LCD), that presents the graphical user interface (GUI) to the user, which includes all of the adjustable controls and alarms, as well as displays waveforms, loops, digital monitors and alarm status. Input devices 26 may include an analog resistive touch screen overlay for display 24, a set of membrane key panel(s), an optical encoder, etc. Software, executed by processor 22, cooperates with the touch screen overlay to provide a set of context sensitive soft keys to the user, while the membrane key panel provides a set of hard keys for dedicated functions. For example, the user may select a function with a soft key and adjust a particular setting using the optical encoder, which is accepted or canceled by pressing an appropriate hard key. Pneumatics subsystem interface 28 is coupled to control subsystem interface 34, disposed in pneumatics subsystem 30, to send commands to, and receive data from, the pneumatics subsystem 30 over a high-speed serial channel, for example.
Processor 22 generally controls the delivered oxygen concentration to the patient based on the desired arterial oxygen concentration, input by the user, and the measurement data and status information received from sensor 10. For example, processor 22 performs gas calculations, controls all valves, solenoids, and pneumatics subsystem electronics required to deliver blended gas to the patient. Additionally, processor 22 manages the GUI, including updating display 24, monitoring the membrane keypad, analog resistive touch screen, and optical encoder for activity. The gas control processes executed by processor 22 are discussed in more detail below.
Pneumatics subsystem 30 contains all of the mechanical valves, sensors, microcontrollers, analog electronics, power supply, etc., to receive, process and deliver the gas mixture to the patient. In a preferred embodiment, pneumatics subsystem 30 includes, inter alia, control subsystem interface 34, one or more optional microcontrollers (not shown), oxygen inlet 36, air inlet 37, gas mixture outlet 38, an optional exhalation inlet 39, and gas delivery mechanism 40, which blends the oxygen and air to form a gas mixture having a delivered oxygen concentration, and then delivers the gas mixture to the patient through gas mixture outlet 38. In one embodiment, pneumatics subsystem 30 receives oxygen through oxygen inlet 36 and high-pressure air through air inlet 37, filters and blends these gases through a gas blender, and then delivers the appropriate pressure or volume of the gas mixture through gas mixture outlet 38. In another embodiment, pneumatics subsystem 30 receives oxygen through oxygen inlet 36 and high-pressure air through air inlet 37, filters these gases, and then delivers the a calculated flow rate of air and a calculated flow rate of oxygen to the patient outlet such as to provide the appropriate pressure or volume of gas mixture with the required fraction of oxygen FiO2 through gas mixture outlet 38. In a further embodiment, pneumatics subsystem 30 receives oxygen pre-mixed with an alternate gas, such as nitrogen, helium, 80/20 heliox, etc., through air inlet 37, and control subsystem 30 adjusts blending, volume delivery, volume monitoring and alarming, as well as FiO2 monitoring and alarming, based on the properties of the air/alternate gas inlet supply. A heated expiratory system, nebulizer, and compressor may also be provided.
In one embodiment, control subsystem 20 and pneumatics subsystem 30 are respectively accommodated within separate physical modules or housings, while in another embodiment, control subsystem 20 and pneumatics subsystem 30 are accommodated within a single module or housing.
In one embodiment, inlet pneumatics 41 includes a manifold with region or country specific “smart” fittings for high-pressure (e.g., 20 to 80 psig) air and oxygen, sub-micron inlet filters that remove aerosol and particulate contaminants from the inlet gas, pressure transducers that detect a loss of each inlet gas, a check valve on the air inlet, and a pilot oxygen switch on the oxygen inlet. The oxygen switch acts as both an oxygen shut off valve when no power is applied, and a check valve when power is applied. A downstream air regulator and O2 relay combination may also be used to provide balanced supply pressure to the gas blending system. The air regulator reduces the air supply pressure to 11.1 PSIG and pilots the O2 relay to track at this pressure. When compressor 49 is provided, the air supply pressure is regulated from about 5 PSIG to about 10 PSIG, or, preferably, from about 6 PSIG to about 9.5 PSIG.
When supply air pressure falls below about 20 PSIG, compressor 49 is activated to automatically supply air to the oxygen blender 42. When compressor 49 is not provided, the crossover solenoid opens to deliver high-pressure oxygen to the air regulator, allowing the air regulator to supply regulated O2 pressure to pilot the O2 relay. Additionally, oxygen blender 42 simultaneously moves to a 100% O2 position, so that full flow to the patient is maintained. Similarly, when oxygen pressure falls below about 20 PSIG, the crossover solenoid stays closed, the oxygen switch solenoid is de-energized, the blender moves to 21% O2, and the regulated air pressure provides 100% air to oxygen blender 42.
Oxygen blender 42 receives the supply gases from the inlet pneumatics 41 and blends the two gases to a particular value provided by control subsystem 20. In one embodiment, oxygen blender 42 includes a valve, stepper motor, and drive electronics.
Accumulator 43 is connected to the outlet manifold of oxygen blender 42 using a large-orifice piloted valve, in parallel with a check-valve. Accumulator 43 stores blended gas from oxygen blender 42, which increases system efficiency, and provides the breath-by-breath tidal volume and peak flow capacity at relatively lower pressure, advantageously resulting in lower system power requirements. Accumulator gas pressure cycles between about 2 PSIG and about 12 PSIG, depending on the tidal volume and peak flow requirements. An accumulator bleed orifice allows approximately 6 liters/min of gas to exit the accumulator, thereby providing a stable O2 mix even with no flow from the flow control valve. A pressure relief valve provides protection from pressure in excess of about 12 PSIG. A water dump solenoid may be activated periodically, for a predetermined period of time, to release a respective amount of gas from accumulator 43 in order to purge any moisture that may have accumulated. A regulator is attached just down stream of the accumulator to provide a regulated pressure source for the pneumatics. A bleed flow of approximately 0.1 liter/min is sampled by an O2 sensor to measure the delivered FiO2. In another embodiment, accumulator 43 may be omitted from gas delivery mechanism 40.
A flow control system provides the desired flow rate of gas mixture to the patient, and includes flow control valve 44 and flow sensor 45, as well as a gas temperature sensor and circuit pressure sensors. The high-pressure gas stored in accumulator 43 feeds flow control valve 44, which is controlled by control subsystem 20 via control subsystem interface 34. Flow sensor 45, along with the gas temperature sensor and the circuit pressure sensors, provide feedback to control subsystem 20. Periodically, control subsystem 20 reads the sensors, calculates and provides a position command to flow control valve 44. Control subsystem 20 adjusts for flow, gas temperature, gas density, and backpressure. The flow proportional pressure drop is measured with a pressure transducer, suitably nulled using one or more auto zero solenoids. Importantly, when the patient is a neonate, the check/bypass valve is closed, and the gas mixture continues to flow from oxygen blender 42 to accumulator 43 to provide the required minimum blender flow, but the gas mixture does not flow back from accumulator 43 to the patient circuit. This advantageously minimizes the time taken for a change in set oxygen fraction to reach the patient outlet.
Safety/relief valve and outlet manifold 46 includes, inter alia, a three way safety solenoid, a piloted sub ambient/over pressure relief valve, and a check valve. Safety/relief valve and manifold 46 prevents over-pressure in the breathing circuit, and allows the patient to breath ambient air during a “safety valve open” alarm. A safe state can also be activated due to a complete loss of gas supplies or complete loss of power. The pressure relief valve is a mechanical relief valve that will not allow pressure to exceed a certain value with a maximum gas flow of about 150 liter/min. The sub ambient valve is piloted with the safety solenoid and on loss of power or a “vent inop” the safety solenoid will be deactivated, which causes the sub ambient valve to open allowing the patient to breath ambient gas. In this case, the check valve helps to insure that the patient will inspire from the sub ambient valve and expire through the exhalation valve thus not rebreathing patient gas.
In a preferred embodiment, the delivered gas is forced into the patient by closing a servo-controlled exhalation valve. The patient is allowed to exhale by the exhalation valve, which also maintains baseline pressure or PEEP. The exhaled gas exits the patient through the expiratory limb of the patient circuit and, in one embodiment, re-enters pneumatics subsystem 30 through exhalation inlet 39, passes through a heated expiratory filter to an external flow sensor, and then out through an exhalation valve to ambient air.
Advantageously, the gas volume may be monitored at the expiratory limb of the machine or at the patient wye, which allows for more accurate patient monitoring, particularly in infants, while allowing the convenience of an expiratory limb flow sensor protected by a heated filter that is preferred in the adult ICU. And, both tracheal and esophageal pressure may be measured. An optional CO2 sensor, such as, for example, a Novametrix Capnostat 5 Mainstream CO2 sensor, may be attached to the breathing circuit at the patient wye, connecting to the control subsystem 20 through a serial communications port, to provide monitoring of the end-tidal pressure of the exhaled CO2 and the exhaled CO2 pressure waveform. When used in conjunction with a wye flow sensor, or when breathing circuit compliance compensation is enabled, the CO2 pressure waveform may also be used to derive secondary monitors.
Operator input 82 includes, inter alia, sensor data thresholds, a desired percentage of FiO2 and an FiO2 low threshold, corresponding to the lowest acceptable FiO2 value. Sensor data 80 include sensor measurements and associated status information, such as, for example, signal quality indicators, etc. In a preferred embodiment, sensor 10 is a pulse oximeter, and sensor data 80 include SpO2 measurements, perfusion index, signal quality index, measurement artifact indicators, sensor failure data, etc. Operator input 82 correspondingly includes an SpO2 low threshold, corresponding to the low point of the intended SpO2 target range, and an SpO2 high threshold, corresponding to the high point of the intended SpO2 target range.
Closed-loop FiO2 control process 90 provides sensor data filtering 92, FiO2 control 94 and output processing 96. Sensor data filtering 92 receives measurement data representing the oxygen concentration in the patient's bloodstream, associated status information and sensor data thresholds, processes the sensor data, and determines whether the measurement data is valid. In one embodiment, an oxemia state, indicating the level of oxygen concentration in the patient's bloodstream relative to a low range, a normal range and a high range, is determined from the measurement data. FiO2 control 94 receives the processed sensor data and oxemia state, sensor data thresholds, the desired percentage of FiO2 and the FiO2 low threshold, and determines the delivered FiO2, as well as other operating parameters for pneumatic module 30, such as gas mixture flow rate, delivery pressure, etc. Output processing 96 converts the delivered FiO2 and operating parameters to specific commands for gas delivery mechanism 40, as well as other pneumatic module 30 components, as required.
In a preferred embodiment, FiO2 control 94 controls the delivered FiO2 based on the desired oxygen concentration, the measured oxygen concentration, an FiO2 baseline and an FiO2 oxemia state component. The FiO2 baseline represents the average level of FiO2 required to maintain the patient in a stable normoxemia state, while the FiO2 oxemia state component provides for different control algorithms, such as proportional, integral, proportional-integral, etc.
Advantageously, FiO2 control 94 ensures that the oxygen concentration in the patient's bloodstream does not fall below a low threshold, nor rise above a high threshold, when the sensor data is determined to be invalid. This determination is based not only on the representative oxygen concentration measurements, but also, and importantly, on the status information associated with the sensor measurements. For example, while sensor module 12 may provide a particular measurement value that appears to fall within a normal oxygen concentration range, this data may actually be suspect, as indicated by one or more associated confidence metrics provided by sensor module 12.
In the pulse oximeter embodiment, sensor data filtering 92 receives SpO2 low and high thresholds, and examines measured SpO2, perfusion index, signal quality index, measurement artifact indicators, sensor failure data, etc., to determine whether the SpO2 measurement is valid, and stores one or more seconds of SpO2 data. The oxemia state is determined from the SpO2 measurements and the SpO2 thresholds. In a preferred embodiment, a hypoxemia state (low range) is determined if the SpO2 measurement is less than the SpO2 low threshold, a hyperoxemia state (high range) is determined if the SpO2 measurement is higher than the SpO2 high threshold, and a normoxemia state (normal range) is determined if the SpO2 measurement is between the SpO2 low and high thresholds. While specific values for SPO2 low and high thresholds will be prescribed by the clinician based on the patient's particular need, these thresholds typically fall within the range of 80% to 100%. For example, the SpO2 low threshold might be set to 87%, while the SpO2 high threshold might be set to 93%. The most recent SpO2 measurement may be used in the determination, or, alternatively, a number of prior SpO2 measurements may be processed statistically (e.g., median, mean, etc.) and the resultant value used in the determination.
In this embodiment, FiO2 control 94 receives the processed SpO2 measurement, perfusion index, signal quality index, etc., and oxemia state, SpO2 thresholds, the desired percentage of FiO2 and the FiO2 low threshold, and calculates the delivered FiO2 and other operating parameters for pneumatic module 30. While a specific value for FiO2 low threshold will be prescribed by the clinician based on the patient's particular need, this threshold typically falls within the range of 21% to 100%, such as, for example, 40%. With respect to the FiO2 low threshold, if the calculated value for the delivered FiO2 is less than the FiO2 low threshold, then FiO2 control 94 sets the delivered FiO2 to the FiO2 low threshold value. Similarly, with respect to the SPO2 thresholds if the measured SPO2 is below a lower SPO2 threshold, FiO2 control 94 increases the calculated value for the delivered FiO2, and, if the measured SPO2 is above a higher SPO2 threshold, FiO2 control 94 decrease the calculated value for the delivered FiO2. With respect to the sensor status information, if the perfusion index is less than a perfusion threshold, such as, for example, 0.3%, FiO2 control 94 sets the delivered FiO2 to a predetermined value. Similarly, if the signal quality index is less that a signal quality threshold, such as, for example, 0.3, FiO2 control 94 sets the delivered FiO2 to a predetermined value and optionally triggers an audio or visual alarm. Similar behavior may be adopted for measurement artifact indicators, sensor failure data, etc.
In a further embodiment, in order to linearize the effect of the control of blood oxygen tension, changes in FiO2 in the normoxia and hypoxemias states may be calculated from notional oxygen tension. In this embodiment, FiO2 control 94 first applies a transformation to the SpO2 values to normalize frequency distribution, and then applies one or more linear filters to the transformed SpO2 values. One such transformation is an inverse transform of the oxyhemoglobin saturation curve.
A desired oxygen concentration is first received (210) from a user. As discussed above, the user may input the desired oxygen concentration, such as, for example, the desired percentage of FiO2, using input device(s) 26 and display 24.
Sensor data are received (220) from sensor module 12, or directly from sensor 10, through sensor interface 14. As discussed above, sensor data include a measurement of the amount of oxygen in the bloodstream of the patient and status information associated with the measurement, such as, for example, saturation of peripheral oxygen measurements, arterial oxygen partial pressure measurements, dissolved oxygen in the blood measurements, a perfusion index, a signal quality index, measurement artifacts, sensor status, etc.
The validity of the measured data is then determined (230) based on the value of the measured data and the status information. As discussed above, sensor data filtering 92 receives measurement data representing the oxygen concentration in the patient's bloodstream, associated status information and sensor data thresholds, processes the sensor data, and determines whether the measurement data are valid.
If the measured data are determined to be valid (240), then the FiO2 delivered to the patient is controlled (250) based on the desired oxygen concentration and the measured data. As discussed above, FiO2 control 94 receives the processed sensor data, sensor data thresholds, and the desired percentage of FiO2 and controls the delivered FiO2 based on the desired percentage of FiO2 and the measured oxygen concentration.
On the other hand, if the measured data are not determined to be valid (240), FiO2 control 94 sets (260) the FiO2 delivered to the patient to a predetermined value.
The gas mixture, with the determined FiO2 percentage of oxygen, is then delivered (270) to the patient.
A desired oxygen concentration is first received (210) from a user. As discussed above, the user may input the desired oxygen concentration, such as, for example, the desired percentage of FiO2, using input device(s) 26 and display 24.
Pulse oximeter data are received (222) from the pulse oximeter module, or directly from the pulse oximeter, through sensor interface 14. As discussed above, pulse oximeter data include a measurement of the saturation of peripheral oxygen, SPO2, in the bloodstream of the patient, a perfusion index, a signal quality index, and, optionally, an indication of measurement artifacts, pulse oximeter status, etc.
The validity of the measured SPO2 is then determined (232) based on the value of the measured SPO2 and at least one of the perfusion index and the signal quality index, and, optionally, the measurement artifact indication(s), the pulse oximeter status, etc. As discussed above, sensor data filtering 92 receives the measured SPO2, perfusion index, signal quality index, etc., and SPO2 data thresholds, processes the data, and determines whether the measured SPO2 is valid. Sensor data filtering 92 also determines the oxemia state based on the measured SPO2.
If the measured SPO2 is determined to be valid (242), then the measured SPO2 is categorized within a hypoxemia, normoxemia or hyperoxemia range, and the FiO2 delivered to the patient is controlled (254) based on the desired percentage of FiO2, the measured SPO2, and the respective range. As discussed above, FiO2 control 94 receives the oxemia state, the FiO2 threshold, the processed SPO2, the SPO2 thresholds, and the desired percentage of FiO2 and controls the delivered FiO2 based on the desired percentage of FiO2, the measured SPO2 and the respective range. FiO2 control 94 ensures that the delivered FiO2 to not less than the FiO2 threshold, increases the delivered FiO2 if the measured SPO2 is below the lower SPO2 threshold, and decreases the FiO2 if the measured SPO2 is above the upper SPO2 threshold.
On the other hand, if the measured SPO2 is not determined to be valid (242), FiO2 control 94 sets (260) the FiO2 delivered to the patient to a predetermined value.
The oxygen is then delivered (270) to the patient.
The many features and advantages of the invention are apparent from the detailed specification, and, thus, it is intended by the appended claims to cover all such features and advantages of the invention which fall within the true spirit and scope of the invention. Further, since numerous modifications and variations will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation illustrated and described, and, accordingly, all suitable modifications and equivalents may be resorted to that fall within the scope of the invention.
